1. 1) Salfeld J. G., Nat. Biotechnol., 25, 1369-1372 (2007).
2. 2) van der Neut Kolfschoten M., Schuurman J., Losen M., Bleeker W. K., Martinez-Martinez P., Vermeulen E., den Bleker T. H., Wiegman L., Vink T., Aarden L. A., De Baets M. H., van de Winkel J. G., Aalberse R. C., Parren P. W., Science, 317, 1554-1557 (2007).
3. 3) European Medicines Agency, Committee for Medical Products for Human Use (CHMP). “Guideline on Strategies to Identify and Mitigate Risks for First-in Human Clinical Trials with Investigational Medical Products.”: 〈http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002988.pdf〉, cited 25 September, 2016.
4. 4) Tranter E., Peters G., Boyce M., Warrington S., Br. J. Clin. Pharmacol., 76, 164-172 (2013).
5. 5) Health Labour Sciences Research Grant, Research on Measures for Intractable Diseases, Prion-byo oyobi chihatusei uirusukansensho ni kansuru chosakenkyuhan. “Progressive multifocal leukoencephalopathy Clinical Practice Guideline 2013”.